At AMP, the companies announced a partnership to add Paragon Genomics' NGS target enrichment technologies to the flagship Sophia AI platform worldwide.
Smaller multiplex molecular panels of five or fewer targets will be covered, while a determination of gastrointestinal panel coverage is expected soon.
In the longer term, the two firms plan to use PlexBio's multiplexing technology to develop a full menu of infectious disease assays.
The Gastrointestinal Pathogen Panel is the first of a number of planned infectious disease syndromic panels on the firm's PCR-based system.
The acquisition merges OvaGene's liquid biopsy technology and molecular diagnostics with Etta's point-of-care system.
The assay was demonstrated to be as effective as microscopy and a rapid immunoassay at detecting Plasmodium falciparum in a sample of febrile patients in Nigeria.
Building on a recent point-counterpoint in the Journal of Clinical Microbiology, lab directors discuss pros and cons of large MDx panels for infectious disease testing.
Originally published May 7.
Strong sales of its clinical systems and consumables pushed the firm's top line up 35 percent, while Cepheid turned in its third consecutive quarter of GAAP profitability.
The acquisition is expected to help build Myriad's companion diagnostics franchise.
The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.
A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.
Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.
In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.